NCT02245243已完成1 期
An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Plasma pharmacokinetic parameters: • AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
研究概览
简要总结
The purpose of this study is to evaluate the pharmacokinetic profile, safety, and tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and subjects with mild, moderate, or severe hepatic impairment.
详细描述
pharmacokinetic profile, safety, and tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and subjects with mild, moderate, or severe hepatic impairment. AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Body mass index (BMI) between 18.5 and 40 kg/m2, inclusive.
- •Able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
- •Hepatically Impaired Subjects Only (Groups A, B, and C):
- •Has a clinical diagnosis of cirrhosis and has been classified as having mild (Group A), moderate (Group B), or severe (Group C) hepatic impairment as defined by the Child-Pugh classification system (Section 7.2).
- •Healthy Subjects Only (Group D):
- •Must be in good health as determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, 12 lead electrocardiogram [ECG] results, and physical examination findings
排除标准
- •All Subjects (Groups A through D):
- •Has a clinically significant abnormality in past medical history or at the screening physical examination (excluding hepatic impairment and other related stable medical conditions within the hepatically impaired population of subjects) that in the investigator's or sponsor's opinion may place the subject at risk or interfere with outcome variables of the study. This includes, but is not limited to, history or current cardiac, renal, neurologic, gastrointestinal, respiratory, hematologic, or immunologic disease.
- •History or presence of an abnormal ECG that, in the investigator's opinion, is clinically significant and would preclude study participation.
- •Has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk (history of cholecystectomy is allowed).
- •Has a functioning liver transplant
- •Has a history of drug and/or alcohol abuse within 6 months before Screening
- •Has a history of or current clinically significant mental disorder or an antagonistic personality that compromises the validity of the informed consent.
- •Has donated blood or plasma within 30 days before dosing, or has lost more than 1200 mL of blood within 4 months before the first dose of study drug.
- •Has a history of AIDS or subject has positive results for HIV at Screening.
- •Hepatically Impaired Subjects Only (Groups A, B, and C):
- •Has had clinical exacerbation of liver disease within 14 days before study drug administration (eg, abdominal pain, ascites, nausea, vomiting, anorexia, fever, or worsening of laboratory results related to hepatic function).
- •Has evidence of acute viral hepatitis within 1 month before Day -1, has clinically demonstrable massive tense ascites, has evidence of severe or acute renal failure, has active stage 3 or stage 4 encephalopathy.
- •Healthy Subjects Only (Group D):
- •Has a positive test result for hepatitis B surface antigen or hepatitis C virus antibody.
研究组 & 干预措施
Delafloxacin
Experimental
Single Dose 300 mg IV
干预措施: Delafloxacin (Drug)
结局指标
主要结局
Plasma pharmacokinetic parameters: • AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
时间窗: Baseline through 72 hours post-dose
次要结局
- Safety endpoints: AEs, clinical laboratory results (serum chemistry, coagulation, hematology, and urinalysis), vital sign measurements, 12-lead ECG measurements, and physical examination findings(Baseline through 72 hours post-dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With CancerPainNCT01824524Xian-Janssen Pharmaceutical Ltd.12
已完成
1 期
Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy SubjectsHepatic InsufficiencyNCT01860326Debiopharm International SA32
已完成
1 期
A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic FunctionProstate CancerNCT02001571Cougar Biotechnology, Inc.24
已完成
1 期
Pharmacokinetics of Everolimus in Subjects With Hepatic InsufficiencyHepatic InsufficiencyNCT00968591Novartis Pharmaceuticals34
撤回
2 期
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRSInfections, BacterialNCT05340257GlaxoSmithKline24